ICON Promotes Barry Balfe to CEO Position

Icon Public Limited Company has promoted Barry Balfe to the role of CEO. Icon is a healthcare intelligence and clinical research organization providing outsourced services to pharmaceutical, biotechnology, and medical device companies. Their services include clinical research, commercial positioning, consulting, and laboratory services. Icon offers a range of services across sectors such as biosimilars, biotechnology, medical devices, and pharmaceuticals.

Dublin, Ireland – September 2, 2025 – ICON plc (NASDAQ: ICLR), a leading clinical research organization, has announced the appointment of Barry Balfe as its new Chief Executive Officer, effective October 1, 2025. Dr. Steve Cutler, the outgoing CEO, will continue to serve on the board as a non-executive director to facilitate a smooth transition [1].

Barry Balfe, who has been serving as ICON’s Chief Operating Officer since January 2025, has been appointed to the role of CEO after a comprehensive succession planning process. Prior to his current position, Balfe held various leadership roles within ICON, including President of Functional Services and President of Pharma Solutions, since joining the company in 2019 [1].

ICON’s Chair, Mr. Ciaran Murray, commented, "Barry has an outstanding record of success in leadership positions in ICON, most recently in his role as Chief Operating Officer. Barry’s appointment follows a thorough succession planning process and he is ideally positioned to lead ICON into the future." Mr. Murray also thanked Dr. Steve Cutler for his significant contributions to ICON, noting that Cutler's strong leadership and vision have enabled the company to achieve its market-leading position [1].

Dr. Steve Cutler, who has been with ICON for 14 years, expressed gratitude to the board, executive team, employees, and customers for their support and collaboration. He stated, "I have worked closely with Barry since joining ICON in 2011 and I strongly believe he is the right person to lead ICON to further growth and success" [1].

Barry Balfe, who will be taking over as CEO, expressed his enthusiasm for the role. He stated, "At this pivotal time in our industry, I look forward to leading our teams as we work to accelerate the development of novel therapeutics that benefit patients around the world. Our ability to create value for our customers through increased efficiency and disruptive innovation of clinical development pathways remains our strategic focus and a key driver of ICON’s growth and further success into the future" [1].

ICON plc provides a wide range of outsourced services to pharmaceutical, biotechnology, medical device, and government and public health organizations. These services include clinical research, commercial positioning, consulting, and laboratory services, among others [2]. With headquarters in Dublin, Ireland, ICON employs approximately 39,900 employees in 95 locations across 55 countries as of June 30, 2025 [1].

References:
[1] https://www.businesswire.com/news/home/20250904315076/en/ICON-Announces-CEO-Transition
[2] https://www.marketscreener.com/news/icon-promotes-coo-barry-balfe-to-ceo-role-ce7d59d8db8af72d